There's a new source of funding for life sciences companies in town, providing credit as an alternative to other financing avenues such as venture capital.
AstraZeneca has joined the ranks of pharma companies seeking to bring drugs targeting lipoprotein(a) to market, paying $100 million upfront for rights to a drug developed by CSPC Pharmaceut